Evidence map›Paper›PMID 41726479›Full record

ArticleAMIA ... Annual Symposium proceedings. AMIA Symposium2024

A Reinforcement Learning (RL)-Motivated Simulation Framework for Evaluating Vancomycin Dosing Strategies.

Bingyu Mao, Ziqian Xie, Laila Rasmy, Masayuki Nigo, Degui Zhi

Abstract read
In one paragraph

Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bingyu MaoMcWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, United States.
Ziqian XieMcWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, United States.
Laila RasmyMcWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, United States.
Masayuki NigoDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, United States.
Degui ZhiMcWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, United States.

Funding

Deep Learning Based Pharmacokinetic Model for VancomycinR01AI175699 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI NIGO, MASAYUKI · 2023 to 2025
$2.4M
Clinical foundation model for structured clinical dataR01LM014249 · NLM · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Laila Rasmy Gindy Bekhet · 2023 to 2026
$1.4M
NIAID NIH HHS R01 AI175699NLM NIH HHS R01 LM014249
6 · The paper itself

Abstract

Achieving and maintaining the therapeutic range in vancomycin treatment is important for optimal outcomes. While guidelines and best practices based on empirical studies exist, the theoretical best dosing strategies under various conditions remain illusive. We developed an RL-based simulation framework using a deep learning two-compartment pharmacokinetic model (PK-RNN-2CM) and introduced the area under the time-concentration curve (AUC) reward score, which translates clinical guidelines into an RL reward. Ground truth time-concentration curves were generated from patient-specific data, and simulated curves were produced under different dosing strategies with optional noise perturbations to mimic real-world settings. Evaluation metrics included 24-hour AUC assessments and RMSE. Results indicated that while the low-dosing AUC target (low-doser) and the high-dosing AUC target (high-doser) performed comparably in noise-free conditions, the low-doser achieved slightly higher AUC reward scores under noisy conditions, whereas the high-doser exhibited greater stability. This framework opens new approaches for optimizing vancomycin dosing.

Indexed as

Computer SimulationReinforcement Machine LearningVancomycinAnti-Bacterial AgentsArea Under CurveHumansAnti-Bacterial AgentsVancomycin

Identifiers

PMID41726479
PMCPMC12919618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.